Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 184


Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.

Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V.

Breast Cancer Res Treat. 2019 May 11. doi: 10.1007/s10549-019-05270-4. [Epub ahead of print]


Intraductal fulvestrant for Therapy of ERα-positive Ductal Carcinoma in Situ (DCIS) of the breast- a Preclinical Study.

Wang G, Chen C, Pai P, Korangath P, Sun S, Merino VF, Yuan J, Li S, Nie G, Stearns V, Sukumar S.

Carcinogenesis. 2019 May 2. pii: bgz084. doi: 10.1093/carcin/bgz084. [Epub ahead of print]


Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.

Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, Hertz DL.

Breast Cancer Res Treat. 2019 Feb 12. doi: 10.1007/s10549-019-05158-3. [Epub ahead of print]


TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V.

J Clin Oncol. 2019 Mar 20;37(9):714-722. doi: 10.1200/JCO.2018.78.7986. Epub 2019 Feb 5.


Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ.

J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19.


Survivorship care visits in a high-risk population of breast cancer survivors.

Skuli SJ, Sheng JY, Bantug ET, Zafman N, Riley C, Ruck JM, Smith KC, Snyder CF, Smith KL, Stearns V, Wolff AC.

Breast Cancer Res Treat. 2019 Feb;173(3):701-708. doi: 10.1007/s10549-018-5028-z. Epub 2018 Nov 7.


Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Stearns V, Brufsky AM, Verma S, Cotter MJ, Lu DR, Dequen F, Joy AA.

Clin Breast Cancer. 2018 Dec;18(6):e1239-e1245. doi: 10.1016/j.clbc.2018.07.007. Epub 2018 Jul 30.


TAILORing Adjuvant Systemic Therapy for Breast Cancer.

Stearns V.

N Engl J Med. 2018 Jul 12;379(2):191-192. doi: 10.1056/NEJMe1806329. No abstract available.


Breast Hormone Concentrations in Random Fine-Needle Aspirates of Healthy Women Associate with Cytological Atypia and Gene Methylation.

Lee O, Heinz RE, Ivancic D, Muzzio M, Chatterton RT, Zalles CM, Keeney K, Phan B, Liu D, Scholtens D, Fackler MJ, Stearns V, Sukumar S, Khan SA.

Cancer Prev Res (Phila). 2018 Sep;11(9):557-568. doi: 10.1158/1940-6207.CAPR-17-0323. Epub 2018 Jun 28.


PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers: PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions.

Stearns V, Park BH.

JAMA Oncol. 2018 Oct 1;4(10):1330-1332. doi: 10.1001/jamaoncol.2018.1766. No abstract available.


Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group.

N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4.


CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?

Shah M, Nunes MR, Stearns V.

Oncology (Williston Park). 2018 May 15;32(5):216-22. Review.


A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 Aug;171(1):121-129. doi: 10.1007/s10549-018-4811-1. Epub 2018 May 11.


Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Jacobs MA, Macura KJ, Zaheer A, Antonarakis ES, Stearns V, Wolff AC, Feiweier T, Kamel IR, Wahl RL, Pan L.

Acad Radiol. 2018 Nov;25(11):1405-1414. doi: 10.1016/j.acra.2018.02.010. Epub 2018 Apr 4.


Increasing Physical Activity Amongst Overweight and Obese Cancer Survivors Using an Alexa-Based Intelligent Agent for Patient Coaching: Protocol for the Physical Activity by Technology Help (PATH) Trial.

Hassoon A, Schrack J, Naiman D, Lansey D, Baig Y, Stearns V, Celentano D, Martin S, Appel L.

JMIR Res Protoc. 2018 Feb 12;7(2):e27. doi: 10.2196/resprot.9096.


Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report.

Yeruva SLH, Javadi MS, Stearns V.

Clin Breast Cancer. 2018 Jun;18(3):e277-e280. doi: 10.1016/j.clbc.2017.12.008. Epub 2017 Dec 21. No abstract available.


Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.

Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, Jeter SC, Armstrong D, Emens LA, Fetting J, Wolff AC, Silhy R, Stearns V, Connolly RM.

Cancer. 2018 May 1;124(9):1904-1911. doi: 10.1002/cncr.31260. Epub 2018 Jan 30.


Reply to J.L. Blum et al and S. Lange et al.

Krop I, Ismaila N, Barlow W, Stearns V.

J Clin Oncol. 2018 Feb 1;36(4):430-431. doi: 10.1200/JCO.2017.75.8607. Epub 2017 Dec 11. No abstract available.


Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design.

Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ.

NPJ Breast Cancer. 2017 Sep 21;3:37. doi: 10.1038/s41523-017-0040-8. eCollection 2017. Review.


Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.

Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S.

Breast Cancer Res Treat. 2018 Jan;167(1):107-116. doi: 10.1007/s10549-017-4503-2. Epub 2017 Sep 16.

Supplemental Content

Loading ...
Support Center